Physician profile
Ashley C Willis
NPI 1346337060
$538.33
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.29 · 2021: $24.09 · 2023: $455 · 2024: $26.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $107.84 | 2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $89.21 | 2023 | Jardiance, Emgality, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $87.30 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.67 | 2023-2024 | Jardiance |
| Phadia US INC. | $38.13 | 2019-2023 | Immunocap |
| Amgen INC. | $37.51 | 2019-2023 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $37.03 | 2023 | Farxiga, Breztri |
| Acacia Pharma INC | $24.09 | 2021 | |
| Astellas Pharma US INC | $24.07 | 2023 | Myrbetriq |
| Mylan Specialty L.P. | $19.24 | 2023 | Yupelri |
| Seqirus USA INC | $14.42 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Pfizer INC. | $12.82 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.